僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動物的臨床診斷或治療，非藥用. Nidanilimab （CAN04） is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer （NSCLC） and pancreatic ductal adenocarcinoma （PDAC）